XtalPi, a global leader in AI and robotics-driven innovation, today unveiled XtalGazer™, its next-generation drug crystallization platform. Combining advanced AI algorithms with automated experimentation, XtalGazer™ transforms traditional trial-and-error approaches into data-driven, intelligent design, setting a new standard for solid-state drug development.
A Paradigm Shift in Crystallization Research
XtalGazer™ integrates XtalPi’s proprietary crystal structure prediction (XtalCSP®) and crystallization strategy recommendation technologies with a fully automated experimental platform. This synergy enables:
- Rational Design: Predicting stable crystal forms and optimal experimental conditions before testing begins.
- Automated Execution: 24/7 robotic operations that enhance efficiency, reduce costs, and ensure traceability.
- Direct Characterization: Rapid crystal structure analysis using MicroED technology to accelerate patent strategies and drug development.
“XtalGazer™ represents a significant milestone in our mission to digitize and automate life sciences. By merging AI with robotics, we’re not just improving efficiency—we’re redefining how drug development is approached, delivering tangible value to our partners.”
– Mr. Dalong Hu, Senior Vice President and Head of Chemical Services at XtalPi
“Guided by our vision of innovation, XtalGazer™ exemplifies how advanced computational methods can revolutionize solid-state research. This platform marks the beginning of a new era in intelligent crystallization design, offering unprecedented speed and precision for small-molecule drug discovery.”
– Dr. Guangxu Sun, Head of Solid-State Research at XtalPi
